Inactive Instrument

Sharon Bio-Medicine Ltd.

Equities

532908

INE028B01029

Sharon Bio-Medicine Ltd. Reports Earnings Results for the First Quarter Ended June 30, 2021

August 13, 2021 at 07:00 am EDT

Sharon Bio-Medicine Ltd. announced earnings results for the first quarter ended June 30, 2021. For the first quarter, the company announced total revenue was INR 495.439 million compared to INR 361.774 million a year ago. Net income was INR 44.942 million compared to INR 14.993 million a year ago. Basic earnings per share from continuing operations was INR 7.81 compared to INR 0.13 a year ago.

Latest news about Sharon Bio-Medicine Ltd.

Sharon Bio - Medicine Limited Announces Intimation Regarding Re-Commencement of Manufacturing Facility	Mar. 21	CI
Innova Captab Limited acquired Sharon Bio - Medicine Limited.	23-08-01	CI
Sharon Bio - Medicine Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-30	CI
Sharon Bio - Medicine Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-10	CI
Sharon Bio - Medicine Limited Appoints Rakhi Makhloga as Company Secretary	23-01-24	CI
Sharon Bio - Medicine Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-11	CI
Innova Captab Reportedly Places Bid for Sharon Bio-Medicine	22-08-30	CI
Sharon Bio - Medicine Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-12	CI
Sharon Bio-Medicine Ltd. Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	22-05-17	CI
Sharon Bio-Medicine Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-07	CI
Sharon Bio-Medicine Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-03	CI
Sharon Bio-Medicine Ltd. Reports Earnings Results for the First Quarter Ended June 30, 2021	21-08-13	CI
Sharon Bio-Medicine Ltd. Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	21-06-23	CI
Sharon Bio-Medicine Ltd. Reports Earnings Results for the Third Quarter Ended December 31, 2020	21-02-12	CI
Sharon Bio-Medicine Ltd. Reports Unaudited Earnings Results for the Quarter and Half Year Ended September 30, 2020	20-11-11	CI
Sharon Bio Medicine Limited Reports Unaudited Standalone Earnings Results for the First Quarter Ended June 30, 2020	20-09-11	CI
Sharon Bio-Medicine Ltd. Reports Earnings Results for the Fourth Quarter Ended March 31, 2020	20-06-26	CI
Sharon Bio-Medicine Limited Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended December 31, 2019	20-02-14	CI
Sharon Bio-Medicine Ltd. Reports Earnings Results for the Second Quarter Ended September 30, 2019	19-11-14	CI
Sharon Bio Medicine Limited Reports Standalone Unaudited Earnings Results for the Quarter Ended June 30, 2019	19-08-14	CI
Sharon Bio-Medicine Ltd. Announces Audited Standalone Earnings Results for the Quarter and Year Ended March 31, 2019	19-05-24	CI
Sharon Bio-Medicine Ltd. Provides Update on USFDA Inspection at its API Facility	19-02-22	CI
Sharon Bio-Medicine Ltd. Reports Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2018	19-02-14	CI
Sharon Bio-Medicine Ltd. Closes its Operations at API Plant	19-01-28	CI
Sharon Bio-Medicine Ltd. Appoints Komal Mota as Company Secretary & Compliance Officer	19-01-09	CI

Chart Sharon Bio-Medicine Ltd.

Duration

Period

More charts

Company Profile

Sharon Bio-Medicine Limited is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and commercialization of pharmaceutical products. The Company operates in three segments, which include Active Pharma Ingredients (API's), Formulations and Toxicology. The Company offers various Active Pharmaceutical Ingredients, including Ketoconazole, Trimetazidine Di HCI, Glimepiride, Eperisone HCI, Memantine HCI, Telmisartan, Nifedipine, Aripiprazole and Atomoxetine HCI. The Company offers various intermediate products, including Cis Bromo Benzoate, N-Acetyl-4(4-Hydroxy Phenyl) Piperazine, Cis Tosylate and Tri Ethyl Benzyl Ammonium Chloride. The Company also offers various services, including preclinical toxicology on small animals, chemical process development and scale up, formulation development, analytical method development, drug master file (DMF) and dossier preparation, and commercial manufacturing of intermediates, actives and finished dosages.

Sector

More about the company